콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

A0325450

Alfacalcidol

European Pharmacopoeia (EP) Reference Standard

동의어(들):

1α-Hydroxyvitamin D3, 1α-Hydroxycholecalciferol, Alfacalcidol

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C27H44O2
CAS Number:
Molecular Weight:
400.64
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

생물학적 소스

synthetic

Grade

pharmaceutical primary standard

Agency

EP

API family

alfacalcidol

양식

solid

제조업체/상표

EDQM

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

−20°C

SMILES string

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1

InChI key

OFHCOWSQAMBJIW-AVJTYSNKSA-N

유전자 정보

human ... VDR(7421)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the authority of the issuing pharmacopoeia. For further information and support please go to the website of the issuing pharmacopoeia.

Alfacalcidol is an active metabolite of vitamin D, used as a vitamin supplement due to it longer half-life. It is found to be effective in regulating calcium balance/bone metabolism.

애플리케이션

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

생화학적/생리학적 작용

Synthetic vitamin D3 analog that is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

픽토그램

Skull and crossbones

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 1 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Novel approach for the determination of alfacalcidol in bulk and tablet dosage form using spectrophotometric method
Saeed-Ul-Hassan S, et al.
Latin American Journal of Pharmacy, 32(5), 784-788 (2013)
Laurent Genser et al.
American journal of surgery, 207(1), 39-45 (2013-10-15)
The aim of this study was to evaluate the effect of perioperative alfacalcidol on postoperative hypocalcemia after total thyroidectomy. A total of 219 patients scheduled for total thyroidectomy were randomized into groups not receiving (group A) or receiving (group B)
Steve Y Rhieu et al.
Journal of cellular biochemistry, 114(10), 2293-2305 (2013-04-23)
3-epi-1α,25-dihydroxyvitamin D3 (3-epi-1α,25(OH)2D3), a natural metabolite of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), exhibits potent vitamin D receptor (VDR)-mediated actions such as inhibition of keratinocyte growth or suppression of parathyroid hormone secretion. These VDR-mediated actions of 3-epi-1α,25(OH)2D3 needed an explanation as 3-epi-1α,25(OH)2D3, unlike
Florent Richy et al.
Aging clinical and experimental research, 17(2), 133-142 (2005-06-28)
Alfacalcidol (1-alpha-hydroxyvitamin D3) is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfacalcidol may be metabolized into calcitriol
J D Ringe et al.
Rheumatology international, 28(2), 103-111 (2007-08-02)
While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.